ORIC Pharmaceuticals, Inc. filings document a Nasdaq-listed clinical-stage oncology company focused on therapeutic resistance in cancer. Its 8-K reports furnish financial results and operational updates, clinical presentation materials for rinzimetostat (ORIC-944) and enozertinib (ORIC-114), and Regulation FD investor presentation slides.
Other disclosures cover ORIC's common stock, shelf registration and at-the-market share sales, prospectus supplement activity, emerging growth company status, and annual meeting proxy matters. The proxy record addresses stockholder voting, board governance, compensation oversight, and equity incentive arrangements, including inducement grants under Nasdaq listing rules.
ORIC Pharmaceuticals, Inc. presented updated Phase 1b data for enozertinib (ORIC-114) in first-line EGFR atypical non-small cell lung cancer. At the September 4, 2026 data cutoff, 26 patients had received 80 mg once daily. The presentation reported an 84% confirmed systemic objective response rate, a 70% confirmed central nervous system (CNS) objective response rate, and an 88% six-month landmark progression-free survival rate. Brain metastases were present at baseline in 65% of patients, and 46% had untreated brain metastases. Median progression-free survival and median duration of response were immature.
Six patients (23%) experienced Grade 3 treatment-related adverse events, all resolved with dose modifications; there were no Grade 4 or 5 treatment-related adverse events or treatment-related discontinuations. ORIC plans to initiate Redwood-1, a global Phase 3 registrational trial, in the first half of 2027. The planned trial will enroll approximately 360 patients with PACC and L861X mutations, including patients with untreated brain metastases, and compare enozertinib with physician's choice of osimertinib or afatinib.
Oric Pharmaceuticals, Inc. Chief Financial Officer Dominic Piscitelli exercised 14,000 stock options on October 20, 2026, at an exercise price of $4.36 per share, acquiring 14,000 common shares and selling 14,000 shares at a weighted average price of $13.5279 per share. The sale was made under a Rule 10b5-1 trading plan adopted May 26, 2026; sale prices ranged from $13.50 to $13.65. After the exercise, the reported position was 64,500 stock options.
Oric Pharmaceuticals, Inc. director Richard A. Heyman exercised 3,500 options on October 1, 2026, acquiring 3,500 common shares at an exercise price of $1.60 per share. He sold 3,500 directly held shares, and RAHD Capital, LLC sold 3,200 shares held of record by the LLC; Heyman had voting and investment power over the LLC-held shares. Both sales were effected under a Rule 10b5-1 trading plan adopted by Heyman and RAHD Capital, LLC, and were reported at $12.9141 per share, with trade prices ranging from $12.57 to $13.39. The option entry reports 26,700 shares following the exercise.
Oric Pharmaceuticals, Inc. director Richard A. Heyman filed a notice covering the proposed sale of 8,100 common shares, with an aggregate market value of $109,107. J.P. Morgan Securities LLC is named in the broker field. The notice says some sales are from cashless option exercises that will occur within three months of October 1, 2026.
Oric Pharmaceuticals, Inc. (ORIC) is identified as the issuer in a notice covering a proposed sale of 7,600 common shares by RAHD Capital, LLC; Richard A. Heyman, a director, is named as the LLC’s manager. J.P. Morgan Securities LLC is listed as broker, and the notice gives an approximate sale date of October 1, 2026, and an aggregate market value of $102,372.
Oric Pharmaceuticals, Inc. Chief Financial Officer Dominic Piscitelli exercised options to acquire 13,400 common shares on September 28, 2026, at a $4.36 exercise price. He then sold 13,400 shares at a weighted average of $13.5267 per share; the reported sale-price range was $13.50 to $13.575. The sale was made under a Rule 10b5-1 trading plan adopted May 26, 2026. His reported option position after the exercise was 78,500 options.
Oric Pharmaceuticals, Inc. Chief Financial Officer Dominic Piscitelli exercised 600 options on September 24, 2026, at an exercise price of $4.3600 per share, acquiring 600 common shares. On the same date, he sold 100 shares at $13.5000 per share and 500 shares at $13.5050 per share. The sales were made under a Rule 10b5-1 trading plan adopted on May 26, 2026. The option row reports 91,900 shares following the transaction.
Oric Pharmaceuticals, Inc. (ORIC) reported that Chief Financial Officer Dominic Piscitelli exercised stock options and sold shares on August 26, 2026. He exercised options for 52,000 shares of common stock at $4.36 per share and 25,000 shares at $6.00 per share, acquiring a total of 77,000 common shares. On the same date, he sold 77,000 common shares at an average price of $13.6859 per share in transactions effected pursuant to a Rule 10b5-1 trading plan adopted on May 26, 2026. One option grant includes a vesting schedule where 25% vested on February 1, 2024 and the remaining shares vest monthly thereafter. A referenced common stock position includes 1,680 shares acquired under Oric’s 2020 Employee Stock Purchase Plan.
Oric Pharmaceuticals, Inc. (ORIC) received a Rule 144 notice relating to planned sales of its common stock for the account of officer Dominic Piscitelli. The notice covers up to 229,500 shares of ORIC common stock, with an indicated aggregate market value of $3,098,250, based on shares outstanding of 103,652,656 as of the filing reference. The shares may be sold through J.P. Morgan Securities LLC on Nasdaq, with some shares coming from stock options and equity compensation awards, including cashless option exercises expected to occur within three months of the notice date.
ORIC Pharmaceuticals is a clinical-stage oncology company reporting continued investment in its two lead programs, rinzimetostat and enozertinib. For the quarter ended June 30, 2026, it recorded a net loss of $41.5 million and for the first half of 2026 a net loss of $77.3 million, driven mainly by research and development spending.
Quarterly R&D expense was $36.3 million, up from $30.5 million a year earlier, reflecting increased external costs for rinzimetostat as the program advances. General and administrative expense was $9.0 million. ORIC held $387.6 million in cash, cash equivalents and investments as of June 30, 2026, after raising about $59.9 million net through at-the-market equity sales in the first half.
The company initiated its first global Phase 3 registrational trial, Himalayas-1, evaluating rinzimetostat plus darolutamide in post-abiraterone metastatic castration-resistant prostate cancer, under a supply collaboration with Bayer. Enozertinib continues in Phase 1b studies in EGFR-mutated non-small cell lung cancer, with additional data expected in the second half of 2026. ORIC currently expects its existing cash resources to fund its operating plan into the second half of 2028.